Echocardiographic Imaging in Management of Staphylococcus aureus bacteremia

Overview

About this study

Staphylococcus aureus is responsible for at least 20% of the healthcare associated blood stream infections in the United States. One of the most worrisome complications of S. aureus bacteremia (SAB) is infective endocarditis (IE).Our goal from this project is to prospectively validate the Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT) scoring system and to assess the potential novel risk factors to optimize the PREDICT scoring system prior to formal implementation in clinical practice.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Adults (age ≥ 18)
Positive blood culture for S. aureus
Able to consent to receive a follow-up letter or phone call

Exclusion Criteria:

Patients who decline consent
Children (< 18 years of age)
Patients with no record of negative blood cultures after staring therapy Pregnant patients

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Muhammad Sohail, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Muhammad Sohail, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials